查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2015227

臨床前影像市場：按產品、類型、影像方式、應用和最終用戶分類－2026年至2032年全球市場預測

Preclinical Imaging Market by Product, Type, Imaging Modality, Applications, End Users - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，臨床前影像市場價值將達到 47.5 億美元，到 2026 年將成長至 53.1 億美元，到 2032 年將達到 105.2 億美元，複合年成長率為 12.02%。

主要市場統計數據
基準年 2025 47.5億美元
預計年份：2026年 53.1億美元
預測年份 2032 105.2億美元
複合年成長率 (%) 12.02%

對儀器、試劑和軟體領域的相關人員而言，現代非臨床成像的促進因素和策略重點進行簡要概述。

在技​​術融合、試劑功能擴展和終端用戶需求不斷變化等因素的驅動下，臨床前成像領域正經歷快速發展。本執行摘要概述了影響儀器供應商、試劑開發商、軟體提供者以及參與臨床前研究的機構負責人的當前趨勢。在此背景下，領導者必須權衡科學研究機會與營運現實，例如日益成長的實驗室工作流程整合需求、轉化研究法規的合規性以及多模態資料的協調統一。

多模態整合、試劑專業化、進階分析、監管協調和協作模式如何重新定義臨床前成像。

過去五年，我們見證了多項變革性變化，這些變化正在重塑臨床前影像，使其成為轉化科學的核心驅動力。首先，儀器整合正在加速發展。結合解剖、功能和分子測量的多模態平台正在降低跨平台數據整合的障礙，從而縮短臨床前階段的決策週期。其次，試劑正變得更加專業化和應用特異性。旨在闡明特定生物路徑的造影和示蹤劑使得研究設計和終點選擇更加精準。

評估 2025 年關稅對供應鏈造成的干擾，以及對影響採購和專案連續性的策略採購的應對措施。

美國2025年實施的關稅調整對整個全球臨床前影像供應鏈造成了明顯的衝擊，影響了進口設備和試劑的採購計畫、組件來源和成本結構。先前依賴即時前置作業時間週期和更高的收貨成本，迫使許多供應商重新考慮其採購區域和庫存策略。作為應對措施，一些製造商加快了供應商多元化進程，並擴大了區域組裝，以盡可能減少關稅變化對客戶的影響。

將產品類型、系統類型、模式、應用和最終用戶優先順序與策略定位連結的多維細分框架。

精細化的市場區隔觀點能夠清楚展現整體情況創新和商業性重點的集中方向。從產品角度來看，市場可分為試劑和軟體/服務兩大類。試劑包括生物發光成像試劑、螢光成像試劑、MRI造影劑、PET放射性追蹤劑、超音波造影劑和X光CT造影劑等。如此豐富的產品線驅動著特定成像方式的工作流程，並決定耗材的成本組成、保存期限以及監管要求。同時，軟體/服務為影像重建、定量分析和資料管理提供運算基礎設施，並擴大以雲端訂閱服務的形式提供。

美洲、歐洲、中東和非洲以及亞太地區的區域商業化趨勢和不同的引入管道塑造了市場進入策略。

區域趨勢對臨床前影像領域的商業化路徑和策略重點有顯著影響。在美洲，對轉化研究基礎設施的投資以及密集的生物技術中心網路刺激了對高通量、合規服務和高級分析的需求，促使供應商優先考慮服務的可靠性和檢驗。同時，歐洲、中東和非洲地區呈現異質性格局，不同的監管環境和醫療保健資金籌措模式要求企業採取靈活的商業策略。在這些地區，互通性和當地法規的建議成為企業成功應用的關鍵因素。

模組化硬體、試劑精度、檢驗的分析技術以及有助於客戶維繫。

對主要企業層面的分析揭示了策略選擇如何體現在產品系列、市場進入策略和夥伴關係模式中。領先的儀器供應商正在投資模組化架構，以實現分階段升級和多模態整合，從而在保護客戶資金的同時擴展功能。試劑開發公司意識到，可重複性和監管文件在決定買家信心方面變得越來越重要，因此他們專注於開發具有更高穩定性和批間一致性的高特異性造影和放射性示踪劑。

供應商和買家可採取的策略重點，以增強供應鏈韌性、模組化整合、監管合規性和夥伴關係主導的採用。

產業領導企業可以透過採取一系列切實可行且有利可圖的措施來加速其影響力，這些措施著重於韌性、協作和以客戶為中心的設計。首先，他們可以重新思考供應鏈架構，並引入雙重採購、區域組裝和安全庫存政策，以減輕貿易中斷和零件短缺對其營運的影響。其次，他們可以優先考慮模組化產品藍圖和開放的整合標準，以減少客戶鎖定壁壘，並實現與檢查室需求相符的無縫多模態工作流程。

結合專家訪談、技術基準測試和檢驗的二手資訊的混合方法，可以得出實用且檢驗的見解。

本分析的調查方法結合了質性專家訪談、技術基準測試和二次調查，並採用三角驗證法以確保證據基礎的可靠性。來自不同領域的專家，包括儀器工程師、試劑化學家、成像科學家和採購經理，為解讀特定成像方式的權衡取捨和應用促進因素提供了見解。技術基準測試比較了系統規格、試劑特性和分析能力，以識別趨同和差異化的模式。

我們將技術融合、營運韌性和監管合規性聯繫起來，整合實際結論，以推進轉化臨床前成像。

總之，臨床前影像正處於關鍵的轉折點，技術成熟、試劑進步和精密分析的融合將加速其轉化應用。隨著生態系統向整合化、可重複的工作流程轉型，透過策略性供應鏈重組、採用模組化技術和改進檢驗流程進行調整的相關人員將獲得更大的價值。此外，區域差異凸顯了製定尊重監管多樣性和營運實際情況的本地化商業化策略的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 臨床前影像市場：依產品分類

  • 試劑
    • 生物發光成像試劑
    • 螢光成像試劑
    • 磁振造影劑
    • PET放射性追蹤劑
    • 超音波造影
    • X光CT造影劑
  • 軟體服務

第9章 臨床前影像市場：按類型分類

  • 多模態系統
  • 獨立成像系統

第10章：以影像方式分類的臨床前影像市場

  • 磁粒子成像
  • 磁振造影
  • 微型CT
  • 光學成像
  • 正子斷層掃描
  • 單光子發射電腦斷層掃描

第11章 臨床前影像市場：依應用領域分類

  • 循環系統
  • 藥物發現
  • 免疫學/炎症
  • 感染疾病
  • 神經病學
  • 腫瘤學

第12章 臨床前影像市場：依最終使用者分類

  • 學術和研究機構
  • 合約研究機構
  • 製藥和生物技術公司

第13章 臨床前影像市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 臨床前影像市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 臨床前影像市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國臨床前影像市場

第17章：中國臨床前影像市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Advanced Molecular Vision, Inc.
  • Agilent Technologies, Inc.
  • Angstrom Advanced Inc.
  • Aspect Imaging Ltd.
  • AXT Pty Ltd
  • Berthold Technologies
  • Bruker Corporation
  • Cubresa, Inc.
  • Euro-BioImaging ERIC
  • FUJIFILM Holdings America Corporation
  • GE HealthCare Technologies Inc.
  • IVIM Technology Corp.
  • KUB Technologies, Inc.
  • LI-COR, Inc.
  • Mediso Ltd.
  • Milabs BV
  • Miltenyi Biotec GmbH
  • MR Solutions Ltd.
  • Peira bvba
  • PerkinElmer Inc.
  • Revvity, Inc.
  • Scitech Pty Ltd
  • Siemens AG
  • TriFoil Imaging
  • United Imaging Healthcare Co., Ltd.
Product Code: MRR-030EE48515D3

The Preclinical Imaging Market was valued at USD 4.75 billion in 2025 and is projected to grow to USD 5.31 billion in 2026, with a CAGR of 12.02%, reaching USD 10.52 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.75 billion
Estimated Year [2026] USD 5.31 billion
Forecast Year [2032] USD 10.52 billion
CAGR (%) 12.02%

A concise orientation to contemporary preclinical imaging drivers and strategic priorities for instrument, reagent, and software stakeholders

The preclinical imaging landscape is rapidly advancing, driven by technology convergence, expanding reagent capabilities, and evolving end-user demands. This executive summary synthesizes contemporary dynamics affecting instrument vendors, reagent developers, software providers, and institutional buyers engaged in preclinical research. Within this context, leaders must reconcile scientific opportunity with operational realities such as laboratory workflow integration, regulatory alignment for translational studies, and the rising imperative for multimodal data harmonization.

Throughout the following sections, the narrative emphasizes strategic inflection points rather than static metrics. Readers will find an analysis of transformative shifts across modalities, an assessment of tariff-related impacts on the U.S. supply chain in 2025, and actionable segmentation insight that clarifies who buys what, and why. The intent is to furnish decision-makers with a structured perspective for prioritizing investment, accelerating commercialization pathways, and optimizing partnerships. By focusing on practical implications for procurement, development pipelines, and translational adoption, this introduction sets the stage for targeted recommendations and a rigorous methodology that underpins each conclusion.

How multimodal convergence, reagent specialization, advanced analytics, regulatory harmonization, and collaborative models are redefining preclinical imaging

The past five years have seen several transformative shifts that are reshaping preclinical imaging as a core enabler for translational science. First, instrumentation convergence has accelerated; multimodal platforms that combine anatomical, functional, and molecular readouts are reducing the friction of cross-platform data integration, thereby shortening preclinical decision cycles. Second, reagents are becoming more specialized and application-driven, with contrast agents and tracers designed to interrogate discrete biological pathways, which in turn informs more precise study designs and endpoint selection.

Third, software and analytics have moved from optional add-ons to critical differentiators, as advanced image processing, AI-driven segmentation, and quantitative radiomics enable richer phenotypic characterization. Fourth, regulatory expectations are shifting toward harmonized validation approaches for imaging biomarkers, prompting earlier engagement between developers and regulators. Finally, collaboration models are evolving: academic laboratories, CROs, and industry partners increasingly adopt consortium-based studies and shared infrastructure to distribute cost and accelerate reproducibility. Taken together, these shifts are redefining competitive advantage and operational resiliency across the ecosystem.

Assessment of 2025 tariff-induced supply chain disruptions and strategic sourcing responses that influenced procurement and program continuity

The U.S. tariff adjustments implemented in 2025 introduced measurable friction across global supply chains relevant to preclinical imaging, affecting procurement timelines, component sourcing, and cost structures for imported instrumentation and reagents. Vendors that previously relied on just-in-time imports encountered increased lead times and higher landed costs, prompting several to reassess sourcing geographies and inventory policies. In response, some manufacturers accelerated diversification of supplier bases and increased regional assembly to insulate clients from tariff volatility.

Furthermore, customers experienced a re-prioritization of capital expenditure decisions as procurement teams sought to balance equipment upgrades with operational expenditures tied to consumables and service contracts. The tariff environment also catalyzed negotiations on long-term supply agreements and stimulated interest in regional manufacturing partnerships. Importantly, the tariff impact differed across product categories; high-value, low-volume instruments presented different mitigation options than reagent-heavy consumable flows, which are more sensitive to per-unit cost changes. As a result, stakeholders that proactively revised sourcing strategies and engaged supply chain teams to model tariff scenarios were better positioned to maintain study continuity and protect timelines for translational programs.

A multidimensional segmentation framework linking product categories, system types, modalities, applications, and end-user priorities to strategic positioning

A granular segmentation lens clarifies where innovation and commercial focus are concentrated across the preclinical imaging landscape. By product, the market differentiates between Reagents and Software & Services, where Reagents encompass categories such as bioluminescent imaging reagents, fluorescent imaging reagents, MRI contrasting reagents, PET radioactive tracers, ultrasound contrasting reagents, and X-ray CT contrasting reagents; this spectrum drives modality-specific workflows and dictates consumable cost profiles, shelf-life considerations, and regulatory handling. In parallel, Software & Services deliver the computational backbone for image reconstruction, quantitative analysis, and data management, increasingly packaged as cloud-enabled, subscription-based services.

By type, the ecosystem is characterized by a split between multimodal systems and standalone imaging systems, with multimodal configurations offering integrated workflows that reduce cross-platform variability while standalone systems provide focused capability and lower capital footprints. Imaging modality further stratifies the landscape into magnetic particle imaging, magnetic resonance imaging, micro-computed tomography, optical imaging, positron emission tomography, and single-photon emission computed tomography, each modality presenting distinct sensitivity, spatial resolution, and tracer compatibility trade-offs that shape study design.

Applications drive technical requirements and purchasing logic, as cardiology, drug development, immunology & inflammation, infectious diseases, neurology, and oncology each impose unique endpoint definitions, throughput expectations, and validation needs. End users consolidate the demand side; academic and research institutes prioritize flexibility and methodological transparency, contract research organizations emphasize throughput, reproducibility, and regulatory-grade documentation, and pharmaceutical and biotechnology companies focus on translational relevance, data integration with clinical biomarkers, and vendor accountability. Integrating these segmentation layers yields a nuanced framework for product positioning, commercialization strategy, and prioritization of R&D investments.

Regional commercialization dynamics and differentiated adoption pathways across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape go-to-market strategy

Regional dynamics materially influence commercialization pathways and strategic priorities across preclinical imaging. In the Americas, investment in translational research infrastructure and a dense network of biotechnology hubs stimulates demand for high-throughput, regulatory-aligned services and advanced analytics, prompting vendors to emphasize service reliability and validation. Meanwhile, Europe, Middle East & Africa presents a heterogeneous landscape where regulatory diversity and varied healthcare funding models necessitate flexible commercial strategies; here, interoperability and local regulatory counsel are decisive factors for adoption.

In the Asia-Pacific region, rapid growth in research capacity, combined with expanding clinical trial activity, is driving appetite for scalable systems and cost-effective consumables, while local manufacturing partnerships and academic-industry collaborations are accelerating technology diffusion. Across these regions, differences in labor costs, regulatory timelines, and infrastructure maturity create distinct adoption curves for multimodal platforms versus standalone systems, and they shape where companies prioritize field trials, partnerships, and localized support networks. Understanding these regional contours is essential for aligning distribution strategies, customer education programs, and after-sales service models.

Competitive advantages derived from modular hardware, reagent precision, validated analytics, and integrated service models that drive customer retention

Key company-level insights reveal how strategic choices manifest across product portfolios, go-to-market approaches, and partnership models. Leading instrumentation providers are investing in modular architectures that allow incremental upgrades and multimodal integration, thereby protecting customer capital while enabling feature expansion. Reagent developers are concentrating on high-specificity contrast agents and radiotracers with improved stability and batch consistency, recognizing that reproducibility and regulatory documentation increasingly determine purchaser confidence.

Software and analytics firms are differentiating through validated algorithms, transparent performance metrics, and interoperability with common laboratory information management systems. On the commercial front, several companies are expanding service offerings to include application support, imaging biomarker qualification, and turnkey study execution, which appeals to sponsors seeking single-source accountability. Strategic partnerships between hardware vendors, reagent suppliers, and analytics providers are becoming more prevalent, enabling bundled offerings that reduce integration risk for end users. Ultimately, companies that align technical roadmaps with end-user workflows and regulatory expectations will secure stronger enterprise relationships and longer-term contracts.

Practical strategic priorities for vendors and purchasers to strengthen supply resilience, modular integration, regulatory alignment, and partnership-driven adoption

Industry leaders can accelerate impact by adopting a set of pragmatic, high-return actions focused on resilience, collaboration, and customer-centric design. First, reassess supply chain architecture to incorporate dual sourcing, regional assembly, and safety stock policies that mitigate the operational effects of trade disruptions and component scarcity. Second, prioritize modular product roadmaps and open integration standards to reduce customer lock-in barriers and enable seamless multimodal workflows that align with laboratory needs.

Third, invest in regulatory and validation support services that help customers translate preclinical imaging biomarkers into clinically relevant endpoints; such services increase perceived vendor value and shorten adoption cycles. Fourth, design commercial models that combine capital flexibility with outcome-oriented service tiers, thereby addressing diverse buyer risk profiles. Fifth, cultivate partnerships with academic centers and CROs to co-develop protocols and generate reproducibility evidence that underpins commercial claims. By implementing these targeted measures, organizations can strengthen competitive differentiation, protect operational continuity, and accelerate technology adoption across the ecosystem.

A mixed-methods approach combining expert interviews, technology benchmarking, and triangulated secondary sources to derive practical and validated insights

The research methodology underpinning this analysis blends qualitative expert interviews, technology benchmarking, and triangulated secondary research to ensure a robust evidentiary foundation. Subject-matter experts including instrument engineers, reagent chemists, imaging scientists, and procurement leads informed the interpretation of modality-specific trade-offs and adoption drivers. Technology benchmarking compared system specifications, reagent profiles, and analytical capabilities to identify patterns of convergence and differentiation.

Secondary sources included peer-reviewed literature, clinical translation case studies, regulatory guidance documents, and publicly available technical specifications from manufacturers, which were synthesized to validate trends and to identify areas of consensus versus emerging debate. Throughout the process, findings were cross-checked against practitioner feedback to surface practical implications for study design, procurement, and commercialization. This mixed-methods approach balances technical rigor with market relevance and supports the actionable recommendations provided in this summary.

Synthesizing actionable conclusions that connect technological convergence, operational resilience, and regulatory alignment to advance translational preclinical imaging

In closing, preclinical imaging stands at a pivotal juncture where technological maturity, reagent sophistication, and advanced analytics converge to accelerate translational impact. Stakeholders who adapt through strategic supply chain redesign, modular technology adoption, and strengthened validation pathways will capture disproportionate value as the ecosystem shifts toward integrated, reproducible workflows. Moreover, regional differences emphasize the need for tailored commercialization strategies that respect regulatory diversity and operational realities.

As the market evolves, the organizations that integrate scientific innovation with pragmatic commercialization practices-such as scalable service offerings, partnership-driven protocol development, and clear regulatory engagement plans-will lead adoption and sustain long-term relationships with end users. The insights presented here are designed to inform those strategic choices and to provide a foundation for immediate actions that protect study continuity and enhance translational outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Preclinical Imaging Market, by Product

  • 8.1. Reagents
    • 8.1.1. Bioluminescent Imaging Reagents
    • 8.1.2. Fluorescent Imaging Reagents
    • 8.1.3. MRI Contrasting Reagents
    • 8.1.4. PET Radioactive Tracers
    • 8.1.5. Ultrasound Contrasting Reagents
    • 8.1.6. X-ray CT Contrasting Reagents
  • 8.2. Software & Services

9. Preclinical Imaging Market, by Type

  • 9.1. Multimodal Systems
  • 9.2. Standalone Imaging Systems

10. Preclinical Imaging Market, by Imaging Modality

  • 10.1. Magnetic Particle Imaging
  • 10.2. Magnetic Resonance Imaging
  • 10.3. Micro-Computed Tomography
  • 10.4. Optical Imaging
  • 10.5. Positron Emission Tomography
  • 10.6. Single-Photon Emission Computed Tomography

11. Preclinical Imaging Market, by Applications

  • 11.1. Cardiology
  • 11.2. Drug Development
  • 11.3. Immunology & Inflammation
  • 11.4. Infectious Diseases
  • 11.5. Neurology
  • 11.6. Oncology

12. Preclinical Imaging Market, by End Users

  • 12.1. Academic & Research Institutes
  • 12.2. Contract Research Organizations
  • 12.3. Pharmaceutical & Biotechnology Companies

13. Preclinical Imaging Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Preclinical Imaging Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Preclinical Imaging Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Preclinical Imaging Market

17. China Preclinical Imaging Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Advanced Molecular Vision, Inc.
  • 18.6. Agilent Technologies, Inc.
  • 18.7. Angstrom Advanced Inc.
  • 18.8. Aspect Imaging Ltd.
  • 18.9. AXT Pty Ltd
  • 18.10. Berthold Technologies
  • 18.11. Bruker Corporation
  • 18.12. Cubresa, Inc.
  • 18.13. Euro-BioImaging ERIC
  • 18.14. FUJIFILM Holdings America Corporation
  • 18.15. GE HealthCare Technologies Inc.
  • 18.16. IVIM Technology Corp.
  • 18.17. KUB Technologies, Inc.
  • 18.18. LI-COR, Inc.
  • 18.19. Mediso Ltd.
  • 18.20. Milabs B.V.
  • 18.21. Miltenyi Biotec GmbH
  • 18.22. MR Solutions Ltd.
  • 18.23. Peira bvba
  • 18.24. PerkinElmer Inc.
  • 18.25. Revvity, Inc.
  • 18.26. Scitech Pty Ltd
  • 18.27. Siemens AG
  • 18.28. TriFoil Imaging
  • 18.29. United Imaging Healthcare Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PRECLINICAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PRECLINICAL IMAGING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PRECLINICAL IMAGING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PRECLINICAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PRECLINICAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PRECLINICAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY BIOLUMINESCENT IMAGING REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY BIOLUMINESCENT IMAGING REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY BIOLUMINESCENT IMAGING REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY FLUORESCENT IMAGING REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY FLUORESCENT IMAGING REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY FLUORESCENT IMAGING REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MRI CONTRASTING REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MRI CONTRASTING REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MRI CONTRASTING REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PET RADIOACTIVE TRACERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PET RADIOACTIVE TRACERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PET RADIOACTIVE TRACERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ULTRASOUND CONTRASTING REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ULTRASOUND CONTRASTING REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ULTRASOUND CONTRASTING REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY X-RAY CT CONTRASTING REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY X-RAY CT CONTRASTING REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY X-RAY CT CONTRASTING REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MULTIMODAL SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MULTIMODAL SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MULTIMODAL SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY STANDALONE IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY STANDALONE IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY STANDALONE IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC PARTICLE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC PARTICLE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC PARTICLE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MICRO-COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MICRO-COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MICRO-COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY OPTICAL IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY OPTICAL IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY OPTICAL IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY DRUG DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY DRUG DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 148. GCC PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GCC PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 150. GCC PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 151. GCC PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. GCC PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 153. GCC PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 154. GCC PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 169. G7 PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. G7 PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 171. G7 PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 172. G7 PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. G7 PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 174. G7 PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 175. G7 PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 176. NATO PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. NATO PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 178. NATO PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 179. NATO PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. NATO PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 181. NATO PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 182. NATO PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES PRECLINICAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA PRECLINICAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)